Individualizing gentamicin dosage regimens in burn patients with gram negative septicemia: A cost benefit analysis

J Lyle Bootman, A. I. Wertheimer, D. Zaske, C. Rowland

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Services provided by a clinical pharmacokinetics laboratory were evaluated in terms of an accepted cost-benefit model, and a model to evaluate clinical services provided by the pharmacist is presented. A retrospective study was conducted to evaluate the impact, in terms of patient outcomes, of individualizing gentamicin dosage regimens in severely burned patients. Analysis was conducted using multivariate statistical techniques and appropriate nonparametric and parametric tests to determine significant differences. This analysis provided the necessary data to quantify the impact of the pharmacokinetic service. The findings suggest that significant differences do exist in comparing individually dosed patients against those who were not, based upon discriminant and multiple regression analyses and/or nonparametric tests. Furthermore, the results will be useful for insurance companies, third-party payers, and government agencies in deciding which innovative clinical services should be reimbursed.

Original languageEnglish (US)
Pages (from-to)267-272
Number of pages6
JournalJournal of Pharmaceutical Sciences
Volume68
Issue number3
StatePublished - 1979

Fingerprint

Cost benefit analysis
Pharmacokinetics
Gentamicins
Cost-Benefit Analysis
Sepsis
Insurance
Health Insurance Reimbursement
Government Agencies
Pharmacists
Retrospective Studies
Regression Analysis
Costs
Industry

ASJC Scopus subject areas

  • Molecular Medicine
  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science
  • Pharmacology

Cite this

Individualizing gentamicin dosage regimens in burn patients with gram negative septicemia : A cost benefit analysis. / Bootman, J Lyle; Wertheimer, A. I.; Zaske, D.; Rowland, C.

In: Journal of Pharmaceutical Sciences, Vol. 68, No. 3, 1979, p. 267-272.

Research output: Contribution to journalArticle

@article{189e101ac36c4e10be1c973db2a1a81b,
title = "Individualizing gentamicin dosage regimens in burn patients with gram negative septicemia: A cost benefit analysis",
abstract = "Services provided by a clinical pharmacokinetics laboratory were evaluated in terms of an accepted cost-benefit model, and a model to evaluate clinical services provided by the pharmacist is presented. A retrospective study was conducted to evaluate the impact, in terms of patient outcomes, of individualizing gentamicin dosage regimens in severely burned patients. Analysis was conducted using multivariate statistical techniques and appropriate nonparametric and parametric tests to determine significant differences. This analysis provided the necessary data to quantify the impact of the pharmacokinetic service. The findings suggest that significant differences do exist in comparing individually dosed patients against those who were not, based upon discriminant and multiple regression analyses and/or nonparametric tests. Furthermore, the results will be useful for insurance companies, third-party payers, and government agencies in deciding which innovative clinical services should be reimbursed.",
author = "Bootman, {J Lyle} and Wertheimer, {A. I.} and D. Zaske and C. Rowland",
year = "1979",
language = "English (US)",
volume = "68",
pages = "267--272",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Individualizing gentamicin dosage regimens in burn patients with gram negative septicemia

T2 - A cost benefit analysis

AU - Bootman, J Lyle

AU - Wertheimer, A. I.

AU - Zaske, D.

AU - Rowland, C.

PY - 1979

Y1 - 1979

N2 - Services provided by a clinical pharmacokinetics laboratory were evaluated in terms of an accepted cost-benefit model, and a model to evaluate clinical services provided by the pharmacist is presented. A retrospective study was conducted to evaluate the impact, in terms of patient outcomes, of individualizing gentamicin dosage regimens in severely burned patients. Analysis was conducted using multivariate statistical techniques and appropriate nonparametric and parametric tests to determine significant differences. This analysis provided the necessary data to quantify the impact of the pharmacokinetic service. The findings suggest that significant differences do exist in comparing individually dosed patients against those who were not, based upon discriminant and multiple regression analyses and/or nonparametric tests. Furthermore, the results will be useful for insurance companies, third-party payers, and government agencies in deciding which innovative clinical services should be reimbursed.

AB - Services provided by a clinical pharmacokinetics laboratory were evaluated in terms of an accepted cost-benefit model, and a model to evaluate clinical services provided by the pharmacist is presented. A retrospective study was conducted to evaluate the impact, in terms of patient outcomes, of individualizing gentamicin dosage regimens in severely burned patients. Analysis was conducted using multivariate statistical techniques and appropriate nonparametric and parametric tests to determine significant differences. This analysis provided the necessary data to quantify the impact of the pharmacokinetic service. The findings suggest that significant differences do exist in comparing individually dosed patients against those who were not, based upon discriminant and multiple regression analyses and/or nonparametric tests. Furthermore, the results will be useful for insurance companies, third-party payers, and government agencies in deciding which innovative clinical services should be reimbursed.

UR - http://www.scopus.com/inward/record.url?scp=0018769012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018769012&partnerID=8YFLogxK

M3 - Article

C2 - 106108

AN - SCOPUS:0018769012

VL - 68

SP - 267

EP - 272

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 3

ER -